Quale sarebbe il prezzo per Sigilon Therapeutics, Inc. (SGTX)

Il prezzo per Sigilon Therapeutics, Inc. (SGTX) è $22.47

Qual è la capitalizzazione di mercato per Sigilon Therapeutics, Inc. (SGTX)

La capitalizzazione di mercato per Sigilon Therapeutics, Inc. (SGTX) è $49.76M

Sigilon Therapeutics, Inc. (SGTX) Rapporto P/B

Cambridge, Massachusetts-based Sigilon Therapeutics, Inc., established in 2015, functions as a clinical-stage biotechnology firm dedicated to creating lasting solutions for patients grappling with chronic health conditions. Its primary investigational therapy, SIG-001, is currently undergoing Phase I/II clinical assessment to prevent bleeding episodes in individuals suffering from moderate to severe Hemophilia A. The company's research pipeline also encompasses SIG-005, designed to address the non-neurological symptoms associated with mucopolysaccharidosis type 1; SIG-007, engineered to ensure a continuous and sustained delivery of functional enzymes sufficient to generate clinical improvements and halt the advancement of Fabry disease; and SIG-002, an initiative focused on replacing islet cells for the treatment of Type 1 Diabetes. Furthermore, Sigilon Therapeutics holds a collaborative research and licensing agreement with Eli Lilly and Company for the advancement and market release of SLTx product candidates targeting Type 1 Diabetes. Originally known as Sigilon, Inc., the company officially adopted its current name in June 2017.

Anno	Rapporto P/B	Cambia
Non abbastanza dati per le date fornite.

Anno

Rapporto P/B

Cambia

Non abbastanza dati per le date fornite.

Azienda	Rapporto P/B	Differenza del rapporto P/B	Il paese
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
CSL Limited CSL.AX	2.5054	-	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	3.7087	-	US

Azienda

Rapporto P/B

Differenza del rapporto P/B

Il paese